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a b s t r a c t
Sleep plays a major role in brain health, and cognition. Disrupted sleep is a well-described
symptom of Alzheimer’s disease (AD). However, accumulating evidence suggests suboptimal sleep also increases AD risk. The deacetylase Sirtuin 1 (Sirt 1), encoded by the SIRT1
gene, impacts sleep via its relationship to wake-sleep neurotransmitters and somnogens.
Evidence from animal and human studies supports a significant and complex relationship
between sleep, Sirt 1/ SIRT1 and AD. Numerous hypotheses attempt to explain the critical
impact of Sirt 1/ SIRT1 on wake- and sleep- promoting neurons, their related mechanisms
and neurotransmitters. However, there is a paucity of studies assessing the interaction
between sleep and Sirt 1/ SIRT1, as a principal component of sleep regulation, on AD pathology. In this review, we explore the potential association between Sirt 1/ SIRT1, sleep, and
AD aetiology. Given sleep is a likely modifiable risk factor for AD, and recent studies suggest Sirt 1/ SIRT1 activation can be modulated by lifestyle or dietary approaches, further
research in this area is required to explore its potential as a target for AD prevention
and treatment.
Ó 2022 The Author(s). Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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behaviour and associated variables. The protein Sirtuin 1
(Sirt 1), is associated with both circadian rhythm and the
homeostatic process of sleep via its relationship to wakesleep neurotransmitters and somnogens [13,14]. Accordingly, Sirt 1 plays an important role in cell survival and is
purported to be protective against Ab-amyloid deposition
and AD-related tau pathology [15,16]. Here, we review the
potential associations between Sirt 1, its encoding gene
(SIRT1), sleep regulation and AD. We also discuss some activators of Sirt 1 in the context of AD prevention, and make
recommendations for future research which may aid in further understanding the complex and multi-faceted relationship between Sirt 1/ SIRT1, sleep, and AD aetiology.

Introduction
Poor quality, or insufficient sleep is associated with a wide
range of adverse health outcomes, and subsequent economic
burden [1]. Evidence demonstrates a major role for sleep in
brain health, as well as maintenance of cognitive abilities
by regulating neuroplasticity, processing of information
acquired during wakefulness, and memory consolidation [2].
Suboptimal sleep, characterised by difficulty falling and
staying asleep, multiple and long awakenings and/or
reductions in restorative slow-wave sleep and rapid eye
movement (REM) sleep, is common in older adults [3],
with prevalence increasing with age. Potential underlying
reasons include alterations in sleep behaviour due to aging,
stress, anxiety, medication usage, disease, or a combination
of these factors [4].
An emerging body of literature has focussed on the relationship of sleep disturbance to neurodegenerative disease.
Alzheimer’s disease (AD) patients show clinical symptoms
of sleep abnormalities, with increased fragmentation
frequentlyone of the first reported symptoms or complaints [5]. Electroencephalogram (EEG) recordings in AD
patients demonstrate a significant reduction of slowwave sleep and REM sleep, and disruption of arousal in
response to external factors [6] Moreover, the sleep-wake
cycle in AD is usually disrupted due to nocturnal awakenings and reduced daytime wakefulness following naps
[7–9]. The sleep architecture alterations are hypothesized
to exacerbate cerebral AD pathology; particularly,
enhanced deposition of Ab-amyloid in the brain due to
reduced clearance during deep sleep, which in turn is associated with a worsening of cognitive symptoms [10].
However, accumulating evidence suggests that a bidirectional relationship between sleep and AD exists. Specifically,
rather than simply manifesting as a symptom of AD, poor
quality, insufficient sleep, or excessive daytime napping
[11], are also proposed to increase future risk of AD. Indeed,
a 2017 meta-analysis of sleep studies suggests that individuals with sleep disturbances have an estimated risk for AD that
is 1.55 times higher than those without sleep disturbances,
and the population attributable risk for AD due to poor sleep
is as high as 15 % [12]. This report likely underestimates the
true problem given that many of the included studies relied
on self-report rather than objective sleep measures.
Sleep is regulated by a homeostatic and a circadian process and these two processes control various aspects of sleep

Sirtuins
Sirtuins, also known as Silent information regulator 2
(Sir2) proteins, were first identified in yeast (Saccharomyces cerevisiae); they are a subtype of a conserved family of nicotinamide adenine dinucleotide (NAD)-dependent
protein deacetylases, and are categorized as class III histone deacetylases (HDACs). Sirtuins remove the acetyl
group from both histones and non-histone proteins,
including transcription factors and enzymes. In humans
and other mammals, there are seven sirtuins - Sirt 1 to Sirt
7 - of which, Sirt 1 is the most well-described [17], and is
the focus of this review. In humans, Sirt 1 is encoded by
the SIRT1 gene on chromosome 10 (Chr10q21.3).
Sirtuins are purported to confer beneficial anti-aging
effects, however, levels of these enzymes decrease with
age [18]. For this reason, these enzymes may be a good
candidate for the study of age-related diseases such as
AD [18,19]. In mammals, Sirt 1 has been shown to be associated with aging, calorie restriction, metabolism, cancer,
stress responses, chromosomal stability, cell differentiation, and the circadian clock [20,21]. The mechanisms by
which Sirt 1 declines with age are not known, but its
reduction in both human and animal models is evident
during midlife when age-related changes in wakefulness
and sleep disorders are expected to occur [22,23].
Sirt 1 and Alzheimer’s disease
Sirt 1 has been suggested to potentially have a protective effect against AD by modulating the acetylation
2
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cortex, originates from monoaminergic cells, including
noradrenergic neurons, neurons producing orexin (also
known as hypocretin) and serotonergic neurons. These
neurons have little activity during REM sleep [31]. SPNs
are thought to control sleep through inhibiting wakepromoting centres, including GABAergic neurons in the
ventrolateral preoptic nuclei and melanin-concentrating
hormone (MCH)-producing neurons in the diencephalon
[33,34]. It is apparent, therefore, that the sleep process is
not regulated by a singular molecular mechanism or gene.
Sleep physiology can be studied from two distinct
perspectives: 1) timing of sleep, regulated through the
circadian process (process C) in the brain, which is a
sleep-independent process, and 2) length of sleep, which
is governed by the homeostatic, sleep-dependent, process
(process S) [35,36]. There is potential interaction between
process C and process S in sleep regulation [37]. Process
C in humans is demonstrated by REM sleep, and has a
circadian rhythm which closely associates with body temperature. These processes are rarely influenced by sleep
and wake during the last 24 h [38]. By contrast, external
stimuli such as prior wake or sleep can affect process S
which determines N3, and slow-wave activity in EEG [35].

homeostasis of AD-related proteins and enzymes [19,24]. A
hallmark of AD is the accumulation of Ab-amyloid peptides
in the brain due to the sequential cleavage of the amyloid
precursor protein (APP), initiated by the enzyme bsecretase. In contrast, a-secretase activation suppresses
Ab-amyloid production [16]. Specifically, Sirt 1, by
deacetylation of transcriptional factors related to asecretase and b-secretase enzymes, could reduce Abamyloid burden in the brain [15,16]. For example, Sirt 1
directly induces the transcription of the gene encoding asecretase. Through this mechanism, Sirt 1 removes acetyl
groups from the retinoic acid receptor beta, which is a
main modulator of a-secretase transcription. Furthermore,
induction of a-secretase by Sirt 1 activates the Notch pathway which involves repairing damaged neurons [15]. Sirt 1
can also deacetylate tau to provide sites for ubiquitination
of hyperphosphorylated tau, thereby facilitating its proteasomal degradation and preventing the formation of tau
tangles [25], another pathological hallmark of AD.
Research has shown that Sirt 1 is expressed in neurons
of the hippocampus; a brain region critical for memory and
learning functions, which are impaired in AD [21,26].
Indeed, in AD, Sirt 1 expression in the brain is reduced
and this reduction parallels the accumulation of AD pathology and disease progression [27,28]. Moreover, SIRT1
knockout mice demonstrate cognitive disorders [20], and
Sirt 1 pathway dysregulation has been implicated as a critical mediator of pathogenesis in animal models of AD [29].
Importantly however, animal studies have shown that
SIRT1 gene expression in the hippocampus and other brain
regions can be increased through intervention approaches
such as dietary restriction or physical exercise; suggesting
potential approaches for augmenting Sirt 1-mediated neuroprotection [18,30]. This topic will be considered in
greater detail, later. The following sections discuss the
relationship between Sirt 1 and sleep.

Sirt 1 and sleep - circadian rhythm
As mentioned above, the circadian system is critical for
regulating the timing of sleep. Circadian clock regulators
are categorized as positive and negative. Brain and Muscle
ARNT-Like 1 (BMAL1; also known as Aryl hydrocarbon
receptor nuclear translocator-like protein 1, ARNTL) and
Circadian Locomotor Output Cycles Kaput (CLOCK, and its
paralogue Neuronal Per-Arnt-Sim domain protein 2,
NPAS2) are positive regulators in mammals. These so
called ‘master genes’ drive rhythmic gene expression and
regulate biological functions under circadian control.
BMAL1:CLOCK protein heterodimers initiate the transcription of target genes, including genes that encode periods
(Pers) and cryptochromes (Crys), which are negative circadian clock regulators. The resulting proteins form dimers
which inhibit further transcription of BMAL1 and CLOCK.
This negative transcriptional feedback loop allows the
cycle to repeat via a low level of transcriptional activity,
thereby generating a 24 h rhythm in mammals [39].
CLOCK protein has histone acetyltransferase (HAT)
activity. Animal studies have shown that Sirt 1, with its
deacetylase function, acts against the HAT activity of
CLOCK, subsequently influencing the expression of Cry1,
Per1 and Per2 in mice [40–42]. Deletion of Sirt1 in mouse
models leads to disturbance of circadian rhythm as well
as inability to adjust to a new light–dark cycle. Reduction
of both SIRT1 expression and NAD+ levels with aging could
be a possible mechanism for attenuation of circadian control among older adults [13].

Sleep
In mammals, sleep is divided into stages determined by
cortical electroencephalography (EEG) activity: REM sleep,
and non-REM (NREM) sleep which includes the 3 substages of N1, N2 and N3 (also referred to as slow-wave
sleep). As the most conventional sleep models suggest,
wake-promoting neurons (WPNs) and sleep-promoting
neurons (SPNs) create a ‘‘switch” system in which they
compete for network dominance. In the human brain,
WPNs and SPNs are found in the brainstem and diencephalon, which accounts for < 1 % of neurons. The majority of WPNs and SPNs are in association with different
neurotransmitters, usually with opposing modulatory
effects [31].
WPNs control wakefulness via two pathways. Both
pathways ascend through the midbrain’s paramedian
region before splitting into dorsal and ventral pathways.
The dorsal pathway, which targets the thalamus, arises
from cholinergic neurons. These neurons are most active
during wakefulness and REM sleep, while in NREM sleep
they have little activity [32]. The larger ventral pathway
which innervates the hypothalamus, basal forebrain, and

Sirt 1 and sleep - the homeostatic process
As mentioned above, whilst the circadian system is critical for regulating the timing of sleep, the homeostatic process is responsible for regulating length of sleep.
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circadian-related gene expression including CLOCK and
BMAL1, 2) changes in structures responsible for light transmission and processing, including the pupil and retina, and
3) decreased amplitude of rhythmic behaviours, disturbance of circadian timing and increased prevalence of disordered sleep [59]. Even in healthy older adults without
clinical symptoms of sleep disorders, the aging process is
associated with reduced sleep quality and quantity, reduction in sleep depth and intensity, impairment of sleep
integrity and reduced daytime activity frequently with
diurnal napping [60].
Accumulating evidence demonstrates that circadian
rhythm disturbance in age-related diseases, such as AD,
is even more pronounced, with this manifestation proposed as a biomarker of AD pathology presence and severity [61]. Indeed, some key processes that are implicated in
AD pathogenesis are supposed to follow a circadian
rhythm, including cerebral blood flow, glymphatic system
function, Ab-amyloid clearance, melatonin production
and metabolism [61].
As mentioned earlier, in humans, many neuropeptides,
neurotransmitters and their receptors are proposed to contribute to sleep physiology. In neurodegenerative diseases
such as AD, multiple neurotransmitter systems are
impacted [62,63]. Moreover, impairments of sleep-related
neurotransmitters such as the monoaminergic and cholinergic systems have been broadly reported in AD [64,65],
highlighting a mechanism through which sleep disturbance in AD patients can manifest. Furthermore, Sirt 1
has been shown to impact some of these neuropeptides,
neurotransmitters and their receptors, suggesting complex
interactions via which Sirt 1 can potentially affect sleep,
AD neurobiology and the relationship between the two:
this subject will be discussed in the next sections.

Homeostatic sleep drive (pressure to sleep) increases as
time awake increases, and decreases during sleep, reaching
‘baseline’ after a night of good quality sleep. After sleep
deprivation, lost sleep can be compensated for by increasing sleep time. By contrast, excessive sleep is followed by
decreased sleep propensity. The homeostatic process is
considered an essential regulatory mechanism for sleep.
Delta waves (frequency 0.5–4 Hz) recorded via EEG, are
usually associated with N3 (slow-wave) sleep, characterise
deep sleep, and are regulated by the homeostatic process
[43]. Animal studies suggest a potential role of Sirt 1 in
maintaining delta waves during NREM sleep [23,44]. Consistent with this notion, and with reduced Sirt 1 levels in
aging, human research has revealed that delta power in
EEG shows age-related decline. Importantly, in addition
to sleep quality, delta power has also been linked to longevity, and metabolic complications [45,46]. It is therefore
plausible that Sirt 1 contributes to sleep homeostasis,
although the underlying mechanism requires further
elucidation.
Satoh et al., showed that aged brain-specific Sirt 1overexpressing (BRASTO) transgenic mice have higher
delta power in NREM sleep compared to control mice, with
no difference in delta power during wakefulness, suggesting that aged BRASTO mice have higher quality, or deeper
sleep [44]. Similarly, a study of mice with knockdown of
SIRT1 in the dorsomedial and lateral hypothalamic nuclei,
revealed decreased sleep quality [23]. A recent study in
mice proposed that Sirt 1 appears to mediate sleep quality
through the Sirt 1/ Nk2 homeobox 1 (Nkx2-1)/ orexin type
2 receptor (Ox2r) pathway, which is a major pathway for
maintaining delta power during NREM sleep [44].

Sleep and Alzheimer’s disease
The presence of sleep-wake disturbances in dementia
due to AD is well-established [47]. Crucially, rather than
presenting only as a co-morbidity, mounting evidence
indicates that sleep disturbances increase risk of cognitive
decline and dementia [11,48,49], by modulating neurobiological brain changes. These brain changes include
increased atrophy [50,51], brain Ab-amyloid [52] and tau
pathology [53] (hallmarks of AD), as well as reduced brain
glucose metabolism [54].
Recent studies show the importance of sleep quality for
glymphatic system function in the brain [10]. Increased
delta power and decreased heart rate during sleep have
both been shown to be related to improved glymphatic
flow [55]. Like the lymphatic system in other organs, the
glymphatic system is a ‘housekeeping’ system for the brain
[56], removing metabolic waste products, including tau
oligomers and Ab-amyloid protein which are associated
with AD and cognitive function [57]. Moreover, data from
mice have shown that increased delta power during recovery sleep specifically promotes cognitive performance that
relies on prefrontal brain regions [58].
Circadian changes have been reported in both healthy
aging and age-related diseases such as AD. A recent review
summarized evidence for age-related alterations in various
aspects of the circadian system, including; 1) reduction of

Sirt 1, sleep and Alzheimer’s disease
Orexin
By influencing both WPNs and SPNs within the, brain,
orexin has an essential role in stabilizing sleep and wake
cycles [66]. However, the primary role of orexin appears
to be in the generation of a wake-promoting signal. Studies
suggest that orexin and its receptors also play a role in the
pathogenesis and extent of pathology of neurodegenerative diseases such as AD [67]. Dysregulation of the orexin
system in the presence of AD pathology, and related
changes to sleep disturbance, have been reported [68,69].
In mild cognitive impairment (a stage which often but
not always precedes AD), increased orexin levels in cerebrospinal fluid have been associated with REM sleep
impairment [70,71]. However, the precise mechanism
through which changes in the orexin system might deteriorate sleep in AD requires further elucidation. Nevertheless, it is important to note that orexin also plays a
critical role as a stress regulator. Stress and stress hormones have been linked to both AD, and reduced sleep
quality. Consequently, this additional role of orexin
requires consideration when understanding its relationship to sleep and AD.
4
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AD pathology. Indeed, monoaminergic neurons project into
the hippocampus and regions of the cortex which are significantly affected by both hyperphosphorylated tau and
Ab-amyloid accumulation [79].
SIRT1 is expressed in monoaminergic neurons, where its
presence is critical to normal wakefulness and the integrity
of wake-active neurons. Transgenic whole animal, and
conditional loss of brain SIRT1 in adult mice results in significant wake disturbance and reduction in wake time,
without impairment in sleep consolidation [23]. Other
aspects of this study also revealed an age-related reduction
in SIRT1 in wake-active neurons, excluding serotoninergic
wake-active neurons [23]. Another mouse study revealed
that SIRT1 can modulate monoamine levels by deacetylating Nescient Helix-Loop-Helix 2 (NHLH2), a neuronal transcription factor for the gene (MAO-A) which encodes the
catabolizing enzyme monoamine oxidase A [80]. Moreover, in vitro research demonstrated that overexpression
of microRNA (miR-142) decreased neuronal expression
and subsequent enzymatic activity of MAO-A through
downregulation of SIRT1 [81]. Abnormal microRNA expression has been implicated in the pathogenesis of several
neurodegenerative disorders, potentially via SIRT1mediated altered neurotransmission. Thus, monoaminergic neurotransmitter systems represent another mechanism through which Sirt 1 can potentially impact sleep
and AD.

The orexin type 2 receptor gene (OX2R) is one of the
main Sirt 1 target genes in the hypothalamus. Sirt 1 has
been shown to up-regulate OX2R, particularly in the dorsomedial and lateral hypothalamus. The OX2R pathway
(which also involves orexin type 1 receptor) appears to
have critical effects on arousal, physical activity motivation, and metabolism [72]. Consistent with this notion,
transgenic mice which overexpress Sirt 1 in the brain
demonstrate improved longevity and delayed aging which
has been attributed to dose-dependent upregulation of
OX2R [72]. Collectively, these findings provide a plausible
mechanism(s) through which Sirt 1 can impact sleep and
AD via the orexin system.
Acetylcholine
As part of the arousal system, acetylcholine (ACh) is
critical for waking and for REM sleep. However, direct analysis of ACh has been problematic. Consequently, some
believe that ACh does not regulate sleep, but it is sleep
stages which govern Ach [73]. In AD, basal forebrain
cholinergic nuclei degenerate. Accordingly, choline acetyltransferase and acetylcholinesterase activity decrease,
which appears to be the major reason for cholinergic dysregulation in AD patients [5]. It is possible that the loss of
cholinergic tone is responsible for both cognitive and arousal dysfunction.
Sirt 1 appears to modulate both ACh receptor expression in the brain [14], and choline’s expression [74]
suggesting another mechanism through which Sirt 1 can
potentially
impact
sleep
and
AD.
Cytidine-50 diphosphate- (CDP) choline is an endogenous compound
produced by the body which serves as a choline source in
metabolic pathways for the biosynthesis of ACh. CDPcholine is a neuroprotective substance which exerts significant beneficial effects on memory function and behaviour
[74]. A recent study showed that CDP-choline increases Sirt
1 protein expression in rat brain, conferring neuroprotection [75]. It has also been suggested that alpha 7 nicotinic
ACh receptors can improve Sirt 1 activity, likely by elevating intracellular levels of its cofactor NAD+. Moreover, the
anti-senescence properties of these receptors appear to
be mediated by Sirt 1 [76]. Importantly, in an AD animal
model, treatment with an alpha 7 nicotinic ACh receptor
agonist produced neuroprotective effects coupled with an
improvement in learning and memory ability [77]. It is
conceivable that these beneficial effects were mediated
by Sirt 1.

Melanin-concentrating hormone
The neuropeptide melanin-concentrating hormone
(MCH) contributes to locomotor activity reduction, energy
conservation, and enhancing sleep when energy balance is
positive [82]. It likely also has a critical role in negative
energy balance by reducing activity and REM sleep [83].
Depletion of MCH either by gene knockout or antagonist
is proposed to reduce NREM and REM sleep, increase sleep
fragmentation and heighten alertness [84].
Studies of animal models have shown that increased
MCH results in improved memory, learning and performance [85]. Emerging evidence has also shown that MCH
function is disturbed in AD, and this disturbance correlates
with AD-related phenotypes such as neurofibrillary tangles
of hyperphosphorylated tau. MCH receptors are widely distributed in the hippocampus and cortex; regions which are
vulnerable to AD-related neuropathology and neurodegeneration. Thus, disturbed MCH function in AD and its potential impact on learning and memory performance could be
mediated by a reduction of MCH receptors.
A recent study demonstrated that Sirt 1 in proopiomelanocortin (POMC)-expressing neurons, which promote sleep, is involved in MCH regulation. Therefore, SIRT1
inhibition in these regions might impair MCH functions.
Further, the Sirt 1 (SIRT1)/ Forkhead Box O1 (FoxO1)/ POMC
signalling pathway is proposed as a potential regulatory
mechanism for MCH action [86]. This pathway appears to
contribute to regulation of energy balance and food intake,
and can influence the sleep-wake cycle [87]. Collectively,
this evidence suggests MCH as another target through
which Sirt 1 can potentially impact sleep and AD.

Monoaminergic neurotransmitters
The main roles of monoaminergic neurotransmitter systems in the sleep-wake cycle have been reported broadly
[5,31,32]. These systems are usually most active during
wakefulness, are slow in NREM sleep, cease function before
and after REM sleep, and start firing again before wakefulness begins [78]. Monoaminergic system impairment is
common in AD. Generally, due to the low number of
monoaminergic fibres in the brain, and given these neurons have long, unmyelinated axons, they are more vulnerable to neurological abnormalities such as the presence of
5
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sharply increases [97]. In diurnal species, melatonin
reduces the wake-promoting signal of the circadian clock,
thereby promoting sleep [98].
Nocturnal secretion of melatonin is disrupted with
advancing age and in neurodegenerative disorders such as
AD, furthering abnormal sleep [99]. Melatonin secretion
declines in mild cognitive impairment with the earliest manifestations of AD neuropathology [100,101], and continues to
decline with disease progression [100]. A recent study
reported that mild cognitive impairment patients with
changes in melatonin production show disturbance in the
circadian clock, causing an elevation in wakefulness at night,
and enhanced REM latency [102]. One candidate mechanism
potentially underlying these effects could be the overregulation of monoamine oxidase which occurs in AD, resulting in
depletion of melatonin’s precursor, serotonin [103].
Animal and in vitro studies also suggest melatonin
administration improves AD pathology; potentially protecting against Ab-amyloid production via increased asecretase activity and decreased b- and c-secretases [104–
106]. Moreover, melatonin has been shown to up-regulate
ADAM10 (A Disintegrin and Metalloproteinase 10) in vitro,
through SIRT1 pathway activation [104]. ADAM10 is the
major physiological a-secretase in neurons, responsible for
cleaving APP in a manner that suppresses Ab-amyloid production. These in vitro findings are further supported by an
animal study where the long-term administration of melatonin to aged mice induced beneficial changes to secretase
activity in the hippocampus that were accompanied by
reduction of phosphorylated NF-jB and increased Sirt 1
[106]. Attenuated spatial memory impairment was also evident following melatonin treatment. These findings led the
authors to suggest dietary supplementation, to mitigate
age-related loss of melatonin, as a potential therapeutic
strategy for AD prevention and progression [106].
The impact of melatonin treatment has also been examined in total sleep-deprived rats [107]. Following total
sleep-deprivation, significantly impaired spatial memory
was evident, coupled with drastically reduced Sirt 1 levels
in hippocampal pyramidal and granular cell layers. However, in total sleep-deprived animals receiving melatonin
doses of 5, 25, 50 or 100 mg/kg/day, hippocampal Sirt 1
expression was preserved. These neurobiological benefits
of melatonin treatment were accompanied by considerably
better performance on behavioural testing. Consequently,
the authors proposed melatonin as a potential therapeutic
strategy aimed at preventing memory deficits caused by
total sleep-deprivation, and suggested Sirt 1 may partially
modulate these beneficial effects [107].
Several studies also highlight a major role for Sirt 1 in
the modulation of melatonin function in improving insulin
resistance, aging, and anti-inflammatory effects; [108–
110] factors which impact AD risk and progression. Collectively, the evidence presented in this section suggests
melatonin as another target through which Sirt 1 can
potentially impact sleep and AD.

Adenosine
The neuromodulator adenosine, and its receptors,
appear to be critical for both circadian rhythm and homeostatic sleep drive. Adenosine itself has somnogenic properties and is considered a ‘sleep substance’, modulating the
sleep-wake cycle via its A1 and A2A receptor subtypes (the
most common receptor subtypes in the mammalian brain).
Research has shown that depletion of its derivative adenosine triphosphate (ATP), and an increase of extracellular
adenosine levels, are both positively associated with sleep
patterns [88,89]. Activation of A1 receptors enhances slowwave activity [90], the main indicator of homeostatic sleep
regulation. Moreover, caffeine has been postulated to
mediate the sleep-wake pattern through A2A receptors
[91]. The adenosine-derived signalling molecule, cyclic
AMP, is itself a circadian clock component that indirectly
induces transcription of many circadian genes, as well as
influencing cell cycle timing. AMP kinase, a cellular energy
sensor dependent upon AMP, can phosphorylate multiple
clock proteins, including Sirt 1, thereby upregulating this
enzyme, and influencing downstream pathways. As stated
previously, Sirt 1 function is also modulated by NAD+
cofactor levels: importantly, however, these levels are
influenced by both circadian and metabolic regulation [92].
The neuromodulatory role of adenosine and its receptors has been reported in various neurodegenerative conditions, including AD [93]. Epilepsy is reported in 10 % to
22 % of AD patients, frequently occurring during the early
disease stages, or even before the formation of cerebral
Ab-amyloid plaques [94]. It is believed that global DNA
hypermethylation is associated with chronic epilepsy
[95], and impairment of adenosine homeostasis is involved
in this process. Accordingly, therapeutic adenosine may
improve DNA methylation profiles and thereby ameliorate
epilepsy progression [94]. A recent study demonstrated
that Sirt 1 in the brain is essential for managing epilepsy,
and adenosine improves epigenetic modifications, neuron
survival and synaptic plasticity [93]. However, the influence of adenosine impairment in AD pathophysiology is
complex. In the short term, increased adenosine tone could
have therapeutic properties by suppressing methyltransferase and consequently reducing changes in DNA methylation, which are common in the brain of AD patients
[96]. Moreover, higher adenosine levels, and subsequent
increased A1 receptor activity improves the hyperexcitability and excitotoxicity network in AD parenchyma.
By contrast, increased A2 receptor activity due to increased
adenosine tone results in memory deficit and AD pathology. Collectively, these findings suggest that the positive
effect of elevated adenosine levels are likely receptor
subtype-dependent [96].
Melatonin
Melatonin (N-acetyl-5-methoxytryptamine), a metabolite of the amino acid tryptophan, is produced in the pineal
gland. In humans, melatonin contributes to a number of
physiological processes including regulating circadian
rhythm and sleep physiology. After two hours of endogenous secretion of melatonin at night, sleep propensity

The role of the retina
In mammals, the functional photopigment melanopsin
is localised within intrinsically photosensitive retinal
6
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[126,127]. Animal studies have also shown that calorie
restriction increases Sirt 1 levels in the brain; specifically
in the hypothalamus [72], a brain region that is particularly
vulnerable to AD neuropathology. The anthraquinone compound rhein (4,5-dihydroxyanthraquinone-2-carboxylic
acid), derived from rhubarb, has been shown to reduce
brain Ab-amyloid deposits, neuroinflammation, and ameliorate cognitive impairment in a transgenic mouse model
of AD [128]. The authors attributed the beneficial effects of
rhein treatment seen in these animals to activation of the
Sirt 1/ peroxisome proliferator-activated receptor gamma
coactivator 1-alpha (PGC-1a) pathway, which improved
mitochondrial biogenesis [128]. However, the therapeutic
efficacy of rhein treatment in humans remains to be
determined. The biophenol DOPET (3,4-Dihydroxyphenylethanol) found in olive oil, grape juice, and wine, has also
been evaluated for its effects in an AD mouse model.
DOPET treatment reversed SIRT1 dysregulation and attenuated spatio-cognitive deficits in these animals [129]. The
observed increase in SIRT1 activity was accompanied by
a-secretase-mediated enhanced clearance of neurotoxic
Ab-amyloid, thereby conferring neuroprotection. The
polyphenol resveratrol, found in grapes and grape products
such as red wine, is well established as an activator of Sirt 1
both in vitro and in vivo. Moreover, in studies of AD
patients, high doses of resveratrol have been shown to
reduce AD biomarker levels in cerebrospinal fluid [130],
confer neuroprotection in brain regions affected in early
AD [131], as well as slow cognitive decline and maintain
function in mild to moderate AD [132]. It should, however,
be acknowledged that the beneficial effects of resveratrol
are unlikely to be solely dependent on Sirt 1 activation as
this polyphenolic compound has been shown to modulate
multiple intracellular signalling pathways [133]. However,
whether such sirt 1/ SIRT1-activating strategies as those
described above modulate AD risk, potentially via impacting sleep, remains to be determined, as does their possible
therapeutic role in the treatment of AD.

ganglion cells (ipRGCs), and is involved in the mediation of
non-visual photoreceptive tasks. Melanopsin’s functions
demonstrate that light not only relays information to the
circadian clock but also has a complex interaction with
several
neurological
and
pathological
processes
[111,112]. The body’s reaction to light is critical for regulation of rhythmic physiologic functions such as hormonal
cycles, and expression of the negative circadian clock regulator genes Per and Cry. Thus, ipRGCs play a major role
in adjusting the circadian clock.
Acquired, or inherited depletion of ipRGCs, in neurodegenerative diseases, leads to impairment of dopaminergic
neurons in the retina. Similarly, disturbed light detection,
or transmission onto the retina due to advancing age or
conditions such as cataract, leads to deregulation of circadian synchrony, and subsequent impairment of a wide
range of physiological processes, including sleep. Consistent with these findings, reduction of melanopsin appears
to be involved in insomnia, depression and cognitive
decline [112,113]. Blue light (460 nm), however, has been
proposed to improve cognitive abilities during both daytime and night-time [114,115]. Yet, circadian clock desynchrony could influence exposure, and response, to the blue
light spectrum [116], which in older adults may cause
reduced melatonin levels and impaired alertness [115].
Cohort studies have demonstrated retinal thinning and
retinal vascular disturbance in AD [117]. Moreover, the
presence of AD hallmarks including Ab-amyloid plaques,
hyperphosphorylated tau, and neurodegeneration have all
been reported in the retina of prodromal and symptomatic
AD patients [118]. Indeed, with evolving imaging techniques, recent studies have suggested that an inexpensive
and non-invasive retinal scan might help diagnose AD in
its early stages (reviewed in [118]).
Sirt 1 is present in the retinal pigment epithelium, lens,
cornea, ciliary body, and neuroretina in both animals and
humans [119,120]. In SIRT1 deficient mice, significantly
thinner retinal cell layers and disordered inner and outer
nuclear layers are evident [121], as well as elevated apoptosis of retinal progenitor cells [122]. Sirt 1 plays a critical
role in retinal and ocular systems, and their pathology,
through influencing several mechanisms including aging,
inflammation, oxidative stress, angiogenesis and neuroprotection [123,124]. The expression of SIRT1 in retinal tissue
depends on light, increasing at night-time. This expression
pattern has not been reported in the liver or brain, highlighting tissue or organ-specific regulation of SIRT1 [125].
It is likely that the presence and severity of Alzheimer’s
retinopathy negatively impacts the quantity and quality
of light transmitted to the retina, thereby influencing physiological functions such as sleep, SIRT1 expression, and
their interrelationship.

Future research directions
A growing body of evidence from both animal and
human studies supports the existence of a complex and
multi-faceted relationship between Sirt 1/ SIRT1, sleep,
and AD aetiology. However, further research is required
to fully elucidate this relationship. One recommendation
for future research is the simultaneous measurement of
Sirt 1 and sleep in well-characterised longitudinal cohorts
of aging and AD. Specifically, by measuring Sirt 1 levels in
plasma, serum or cerebrospinal fluid, and sleep parameters
such as efficiency, duration and time spent in sleep stages,
across the AD continuum of preclinical, prodromal and
dementia stages, the relationship between Sirt 1, sleep,
and AD progression could be further elucidated. Moreover,
by including individuals who remain cognitively unimpaired over time (both with and without the presence of
AD biomarkers) in such a study, the effect of healthy versus
pathological aging could also be considered. Such analysis
is important for understanding the impact of age as a
mediator of the Sirt 1/ SIRT1, sleep, and AD relationship,
given that advancing age is the greatest risk factor for

Activators of Sirt 1 - dietary factors and other putative
modifying strategies
Multiple dietary factors, other agents and strategies
have been proposed to activate Sirt 1/ SIRT1. For example,
intermittent fasting, calorie restriction, and calorie restriction combined with exercise have all been shown to
increase levels of Sirt 1 mRNA in human muscle tissue
7
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Fig. 1. Potential interaction between sirtuin 1, sleep, and Alzheimer’s disease. Sirtuin 1 can modulate levels of pathological hallmarks of Alzheimer’s disease
(Ab-amyloid and hyperphosphorylated tau; p-tau). This pathology, via widespread neurodegeneration that impacts sleep-regulating brain regions, is associated
with disrupted sleep; one of the most common symptoms of Alzheimer’s disease. Sirtuin 1 can also directly impact sleep via effects on both circadian rhythm (Process
C) and homeostatic sleep drive (Process S). In addition to being a symptom of Alzheimer’s disease, suboptimal sleep has also been linked to increased risk of
Alzheimer’s disease via reduced brain Ab-amyloid clearance, oxidative stress and inflammation. Sirtuin 1 has been shown to impact multiple neuropeptides,
neurotransmitters and their receptors, suggesting complex interactions via which Sirtuin 1 can potentially affect sleep, Alzheimer’s disease neurobiology, and the
relationship between the two. These neuropeptides and neurotransmitters include orexin, acetylcholine, monoaminergic neurotransmitters, melanin-concentrating
hormone, adenosine, and melatonin.

AD, sleep changes with age, and Sirt 1 is associated with
anti-aging effects. Once the relationship between Sirt 1/
SIRT1, sleep, and AD aetiology has been well characterised,
the logical next step would be to investigate the impact of
Sirt 1 activators (e.g., resveratrol, dietary approaches
including intermittent fasting and calorie restriction, etc.)
on sleep parameters and AD biomarkers measured simultaneously. This may inform how such approaches could
potentially be employed in the development of strategies
aimed at delaying or ideally preventing the onset of
dementia due to AD.
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